Tuesday, July 24, 2007
After intense research, the maker of anti-osteoporosis drug Evista is asking the FDA to approve its use against breast cancer. A related drug, Tamoxifen, is already widely used by breast cancer survivors. If approved this would be a particularly interesting development because breast cancer survivors at increased risk of osteoporosis, often because of their medication regimes for cancer. In contrast, this medicine might help protect their bones. Read more at: http://www.thestreet.com/s/fda-mulls-new-use-for-lilly-drug/newsanalysis/pharmaceuticals/10369172.html?puc=_googlen?cm_ven=GOOGLEN&cm_cat=FREE&cm_ite=NA
